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The suitability and accuracy of using simple human immunodeficiency virus (HIV) rapid (SR) tests in
community-based clinics in northwest Tanzania were determined to assess eligibility for participation in
clinical trials. The HIV rapid and ELISA test results for 789 women aged 16 to 54 who were screened for two
clinical trials of HIV prevention were compared. Women were offered voluntary HIV counseling and testing
(VCT) at screening; those who accepted were tested with the Abbott Determine and Trinity Biotech Capillus
SR tests in parallel. The results were confirmed by two parallel HIV enzyme-linked immunosorbent assay
(ELISA) tests (Abbott Murex HIV Ag/Ab combination and Vironostika Uniform II HIV Ag/Ab) to determine
eligibility. Positive samples for any of the four assays were confirmed by a line immunoassay and p24 testing.
The parallel SR tests had high concordance (96.2%) with the parallel ELISA algorithm. The sensitivities of the
SR tests were 98.6% for Capillus (95% confidence interval [CI], 95.1 to 99.8%), 99.3% for Determine (95% CI,
96.2 to 100%), and 98.6% for the parallel SR (95% CI, 95.1 to 99.8%). The specificities were 99.7% for Capillus
(95% CI, 98.9 to 100%), 99.7% for Determine (95% CI, 98.9 to 100%), and 100% for the parallel SR (95% CI,
99.4 to 100%). SR tests are suitable for use in community-based clinical research settings to assess eligibility
both for trial participation and for the provision of on-site VCT services.
Antibody testing for human immunodeficiency virus (HIV)
began with the introduction of enzyme-linked immunosorbent
assays (ELISA) in the 1980s. Those tests, together with West-
ern blotting, formed the cornerstone of HIV testing algorithms
until 1992, when the Global Programme on AIDS of the World
Health Organization (WHO) first recommended the use of
simple rapid (SR) tests (14). SR tests have been recommended
for use in blood safety screening, in surveillance, and in diag-
nosis in prenatal or voluntary counseling and testing (VCT)
centers (15). SR tests have been widely used throughout Africa
and the developing world.
By the end of 2007, an estimated 33.2 million people were
living with HIV/AIDS, with 2.5 million people being newly
infected and 2.1 million dying during 2007 (9). More than 60%
of those infected were in sub-Saharan Africa (9). Even in
circumstances where treatment is widely available, the inci-
dence remains high, and identifying new interventions for the
prevention of HIV must therefore remain a research priority
(11).
HIV prevention trials frequently use community-based clin-
ics for screening, recruitment, and distributing trial products to
participants. These clinics are often located far from a central-
ized laboratory. In most HIV prevention trials, HIV screening
is an essential procedure to assess eligibility for the trial, for
which participants must be HIV negative to be eligible for
enrollment. In these settings, SR tests offer many advantages
over laboratory-based testing. SR tests are simple to use, re-
quire little or no equipment, are cheaper than laboratory-
based HIV antibody tests, can be stored at room temperature,
and are easy to read. They allow for real-time, on-site HIV
testing so that both VCT, if offered as part of the clinical care
package provided by the trial, and trial screening can be of-
fered in one visit. Individuals can receive their test results
immediately, which is of personal benefit and likely to increase
the uptake of VCT as well as being a more efficient way to
screen volunteers for HIV prevention research. There is no
need for a second visit to collect negative results, although
positive SR results may have to be confirmed by a laboratory-
based assay according to trial-specific procedures.
SR tests are particularly suited for use in sub-Saharan Af-
rica, where up to 2 weeks or more may be needed for labora-
tory results to become available (8). Indeed, studies have
shown that SR tests can greatly enhance VCT services, espe-
cially in rural areas (5, 7, 13). In contrast, the use of a central-
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ized laboratory may result in reporting delays, which may slow
trial recruitment or affect follow-up rates during the trial, if
participants must return for a second visit to get their test
results. Data from a number of evaluations suggest that the
sensitivity and specificity of SR tests are similar to those of
ELISA- and Western blotting-based algorithms (6, 16). How-
ever, more recent studies have reported lower-than-expected
sensitivities and specificities of SR tests (1, 4). Therefore, for
use in clinical trials, SR tests should be validated locally and
undergo external quality assessment. We report a validation
exercise carried out for two clinical trials in northwest Tan-
zania, comparing SR test results from the field with double
ELISA tests conducted in our main testing laboratory in
Mwanza, Tanzania.
MATERIALS AND METHODS
Study design. Subjects for our validation study were participating in two large
community-based clinical trials in northwest Tanzania, one in Mwanza City and
the other in 19 sites in the Lake Victoria region.
The first is a six-center, randomized, double-blind, placebo-controlled trial of
a candidate vaginal microbicide (PRO2000/5) for HIV prevention, being con-
ducted in four countries in sub-Saharan Africa (10). The Mwanza City site is
enrolling women aged 16 years and older, working in bars, guesthouses, and
other food and recreational facilities. After informed consent, women are offered
VCT, interviewed at community-based reproductive health clinics, asked to pro-
vide specimens for HIV/sexually transmitted infection (STI) and pregnancy test-
ing, and given their HIV results by trained counselors. Those that are HIV
negative are invited to participate in enrollment within 6 weeks and are then
followed up every 4 weeks for 52 weeks. At the screening visit, in addition to
parallel SR tests in the field, all samples are tested for HIV by ELISA.
The second trial, which has recently been completed, was a randomized,
double-blind, placebo-controlled trial of acyclovir, 400 mg twice daily, in women
who were herpes simplex virus type 2 (HSV-2) seropositive (12). The trial
investigated whether suppressive therapy for herpes could reduce either HIV
incidence in women who were HIV negative or HSV-2/HIV genital viral shed-
ding in dually infected women. In total, 2,735 female food and recreational
facility workers aged 16 to 35 years were screened for antibodies to HIV and
HSV-2, and 1,305 HSV-2 seropositive women (821 HIV negative and 484 HIV
positive) were enrolled from 19 communities at mobile health clinics. After
informed consent, women were interviewed and examined, provided specimens
for HIV/STI and pregnancy testing, and were asked to follow up every 3 months
for 12 to 30 months, depending on the enrollment date. Participants were offered
free VCT by a trained counselor at each visit. In addition, all samples were tested
in Mwanza for HIV by ELISA at screening, enrollment, and the end of the
follow-up period to determine HIV seroconversion for participants who were
initially HIV negative.
Whole blood and serum specimens were used for this validation study. It
includes data from all women screened for the microbicide trial from January
to June 2006 (n  257). In the HSV suppressive treatment trial, serial SR
tests were initially used at screening and parallel SR tests at enrollment. This
validation study, therefore, uses enrollment specimens (n  382) and screen-
ing specimens after June 2004 (n  150) when parallel testing was introduced
at screening.
HIV assays. Whole blood was tested using the Determine HIV-1/-2 SR test
(Abbott Laboratories, United Kingdom) and the Capillus HIV-1/-2 SR test
(Trinity Biotech, Ireland) in parallel. All SR tests were performed on-site in the
community-based clinics by trained counselors and pre- and posttest counseling
was provided at the same visit. Participants found to be HIV positive were
referred to the nearest centers providing HIV care and support services.
Serum was tested using the Murex HIV Ag/Ab combination ELISA (Murex
Biotech, Dartford, United Kingdom) and the Vironostika Uniform II HIV
Ag/Ab ELISA (BioMe´rieux, France) in a parallel testing strategy. All ELISAs
were performed at the National Institute for Medical Research (NIMR) Mwanza
Centre STI Laboratory. The laboratory personnel were blinded to the clinic SR
test results.
In Mwanza, our experience with samples from adolescents in these com-
munities has shown that the majority of the weak positives from ELISA are
actually negative (2). Therefore, the Mwanza STI Reference Laboratory
classifies samples as indeterminate if the optical density/cutoff ratios (OD/
CO) lie in the range of 1.00 to 1.99 for the Murex or Uniform II ELISA. The
samples with different results (positive, indeterminate, or negative) for the
Murex and Uniform II ELISA (e.g., Murex positive/Uniform II negative) are
classified as discordant.
The samples that were negative for both ELISA and both SR tests were
defined as HIV seronegative. All other samples, including samples positive for all
four assays, were sent to the Institute of Tropical Medicine, Antwerp, Belgium,
for testing by the Inno-LIA HIV I/II line immunoassay (LIAInnogenetics, Gh-
ent, Belgium). If a sample was determined to be positive, this was taken as the
final HIV result. The samples that were negative for Inno-LIA were tested by an
HIV-1 p24 Ag enzyme immunoassay (Bio-Rad Genetic Systems, CA). If a sam-
ple was negative for both p24 and Inno-LIA, this was taken as the final HIV
result.
Statistical analysis. Data were double entered into dBase IV or an SQL server
database and analyzed in STATA version 9 (Statacorp, TX). The sensitivity,
specificity, and predictive values of the SR assay and ELISA were calculated. A
true positive was defined as positive for Inno-LIA or positive for p24. A true
negative was defined as negative for Inno-LIA and p24 or negative for Murex,
Uniform, Capillus, and Determine. A test positive for the single assays (Murex,
Uniform, Capillus, or Determine) was defined as positive for that assay; a test
negative was defined as negative for that assay or as negative or indeterminate
for the ELISA. For the parallel SR or ELISA strategies, a test positive was
defined as positive for both assays. A test negative was defined as negative for
either assay or, for the ELISA, as negative or indeterminate for either assay (i.e.,
a negative or discordant overall result for the SR strategy or a negative, inde-
terminate, or discordant overall result for the ELISA strategy).
TABLE 1. Comparison of the results of each assay with those of
the gold standard
Test strategy and result Total no. (%)of samples
No. of samples with
the indicated gold
standard resulta
Positive Negative
Parallel SR
Negative 641 (81.2) 1 640
Discordant 5 (0.6%) 1 4
Positive 143 (18.1%) 143 0
Capillus
Negative 644 (81.6%) 2 642
Positive 145 (18.4%) 143 2
Determine
Negative 643 (81.5%) 1 642
Positive 146 (18.5%) 144 2
Parallel ELISA
Negative 621 (78.7%) 0 621
Discordant/indeterminate 22 (2.8%) 1 21
Positive 146 (18.5%) 144 2
Murex
Negative 632 (80.1%) 0 632
Indeterminate 7 (0.9%) 0 7
Positive 150 (19.0%) 145 5
Uniform
Negative 631 (80.0%) 1 630
Indeterminate 10 (1.3%) 0 10
Positive 148 (18.8%) 144 4
Total 789 (100%) 145 644
a Samples that were negative for all four assays (Murex, Uniform, Capillus,
and Determine) were defined as HIV seronegative. All other samples were
tested by InnoLIA and p24. A true positive was defined as positive for InnoLIA
or p24. A true negative was defined as negative for InnoLIA and p24 or negative
for all four assays.
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RESULTS
The validation study population comprised 789 female food
and recreational facility workers aged 16 to 54 years (mean,
29.0 years; standard deviation, 6.8 years) in northwest Tan-
zania. Based on parallel SR testing with the Determine and
Capillus assays, 143 (18.1%) samples were classified as HIV
positive, 641 (81.2%) were HIV negative, and 5 samples
(0.6%) were discordant (Table 1). Based on parallel ELISA
testing with the Murex and Uniform II assays, 146 (18.5%)
samples were HIV positive, 621 (78.7%) were HIV negative,
and 22 (2.8%) were indeterminate or discordant (Table 1).
The test algorithms for the validation study are detailed in
Fig. 1 and 2. Overall, 172 (21.8%) samples were positive or
indeterminate for at least one SR test or ELISA and went for
InnoLIA testing for confirmation. Among those, 145 (18.4%)
were confirmed positive. A total of 142 (18.0%) samples were
HIV positive for both SR tests and both ELISAs, and 617
(78.2%) were HIV negative for all four tests (Table 2). Overall
concordance, defined as the proportion of samples that were
positive for all four tests or negative for all four tests, between
the parallel ELISA and parallel SR tests was 96.2% (759/789;
95% CI, 94.6% to 97.4%).
The sensitivity and specificity of parallel ELISA testing were
99.3% (95% CI, 96.2 to 100%) and 99.7% (95% CI, 98.9 to
100%) (Table 3), respectively, compared to the gold standard.
The positive and negative predictive values were 98.6% (95%
CI, 95.1 to 99.8%) and 99.8% (95% CI, 99.1 to 100%), respec-
tively. The sensitivity and specificity of the parallel SR testing
were 98.6% (95% CI, 95.1 to 99.8%) and 100% (95% CI, 99.4
to 100%) (Table 3), respectively, compared to the gold stan-
dard. The positive and negative predictive values were 100%
(95% CI, 97.5 to 100%) and 99.7% (95% CI, 98.9 to 100%),
respectively.
DISCUSSION
HIV testing is a key component of HIV prevention trials, for
assessing eligibility, for evaluating the effectiveness of trial
interventions, and as part of the VCT services offered to trial
participants. Although SR tests, on their own, are not sufficient
for the confirmation of seroconversion as a primary trial out-
come, they can play a central role in the service component of
any HIV prevention trial. In community-based trials, SR tests
can allow trial eligibility to be assessed in the field. Further-
more, they can provide an indication of seroconversion during
trial follow-up and alert the investigator to the need for con-
firmatory tests.
Our validation study found that, in field-based settings in
Tanzania, parallel SR tests were slightly more specific and only
slightly less sensitive than ELISA-based algorithms. Although
FIG. 1. Results of simple rapid HIV assays for the diagnosis of HIV infection. , positive (ELISA OD/CO, 2); i, indeterminate (ELISA
OD/CO, 1 to 1.99); , negative (ELISA OD/CO, 0 to 0.99).
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ELISA-based tests are highly accurate, they are impractical for
field conditions in developing countries because of the high
cost, the need for trained personnel and specialized equip-
ment, and the long turnaround time.
Our results demonstrate that the parallel SR strategy can
provide an ideal screening test to assess eligibility for HIV
prevention trials. Its sensitivity against the gold standard was
98.6% with one true HIV-positive participant having negative
results on both SR tests and one having discordant results on
the two tests. In practice, the latter would undergo further
evaluation, and so only one true positive would have been
missed completely by this algorithm, corresponding to a sen-
sitivity of 99.3%. In a clinical trial, the few HIV-positive cases
missed by rapid testing would be detected through subsequent
HIV testing during the trial, at which time back testing could
be done using more sensitive tests to see whether the partici-
pant was HIV positive at entry. In contrast with the parallel
ELISA algorithm, the parallel SR tests gave only a few discor-
dant results, reducing the need for further testing to determine
trial eligibility. Finally, the parallel SR algorithm was highly
specific, 100% in our study population, suggesting that partic-
ipants with positive results can be referred to HIV care and
treatment centers without the delay of further confirmatory
testing.
The Determine SR test has been reported to have sensitiv-
ities and specificities of 100% and 99 to 100%, respectively (3,
16). Reported sensitivities and specificities of the Capillus SR
test are 99 to 100% (3, 16). We found the specificities of
Determine and Capillus to be within the reported range. How-
ever, we found the sensitivities of both tests to be slightly lower
than reported and the sensitivity of Capillus to be lower than
that of Determine (98.6% and 99.3%, respectively). Poor sen-
sitivity has been reported elsewhere in sub-Saharan Africa (1,
4). In contrast, we found the sensitivities of the Murex and
Uniform II ELISA tests to be 100% and 99.3%, respectively.
The sensitivity of the parallel SR algorithm was 98.6%, com-
pared with 99.3% for the parallel ELISA algorithm. The
ELISAs used in our validation study incorporate a p24 detec-
tion system, which increases the sensitivity of these tests. How-
ever, the specificity of the parallel SR was higher than that of
FIG. 2. Results of the parallel serology testing using ELISA for the diagnosis of HIV infection. , positive (ELISA OD/CO, 2); i,
indeterminate (ELISA OD/CO, 1 to 1.99); , negative (ELISA OD/CO, 0 to 0.99).
TABLE 2. Comparison of parallel ELISA (Murex and Uniform II)
results with parallel SR (Determine and Capillus) results
Parallel ELISA
result
No. (%) of samples with indicated parallel SR result
Negative Positive Discordanta Total
Negative 617 (78.2) 0 4 (0.5) 621 (78.7)
Positive 3 (0.4) 142 (18.0) 1 (0.1) 146 (18.5)
Indeterminateb 1 (0.1) 0 0 1 (0.1)
Discordantc 20 (2.5) 1 (0.1) 0 21 (2.7)
Total 641 (81.2) 143 (18.1) 5 (0.6) 789 (100)
a Discordant SR results: positive (P)/negative (N) or N/P.
b OD/CO between 1.0 and 1.99.
c Discordant ELISA results: P/intermediate (I), I/P, P/N, N/P, I/N, or N/I.
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the parallel ELISA (100% versus 99.7%). The lower specificity
of the parallel ELISA may be a result of cross-reactivity with
other infections that are endemic in this region of Tanzania.
In summary, our results show that in this study population,
with an HIV prevalence of 18%, the parallel SR algorithm had
both high sensitivity and specificity, comparable to the sensi-
tivity and specificity of ELISA-based algorithms. Parallel SR
tests may provide an efficient and accurate way of assessing
eligibility for HIV prevention trials, particularly in resource-
poor settings. Furthermore, such tests may play a valuable role
in the VCT service component of a trial, by allowing HIV-
positive participants to be referred for care and treatment
without delay.
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TABLE 3. Sensitivity and specificity of rapid assays and ELISA for HIV
Assay
% (95% CI) for:
Sensitivity Specificity Positive predictive value Negative predictive value
Capillus 98.6 (95.1–99.8) 99.7 (98.9–100) 98.6 (95.1–99.8) 99.7 (98.9–100)
Determine 99.3 (96.2–100) 99.7 (98.9–100) 98.6 (95.1–99.8) 99.8 (99.1–100)
Parallel SRa 98.6 (95.1–99.8) 100 (99.4–100) 100 (97.5–100) 99.7 (98.9–100)
Murexb 100 (97.5–100) 99.2 (98.2–99.7) 96.7 (92.4–98.9) 100 (99.4–100)
Uniformb 99.3 (96.2–100) 99.4 (98.4–99.8) 97.3 (93.2–99.3) 99.8 (99.1–100)
Parallel ELISAc 99.3 (96.2–100) 99.7 (98.9–100) 98.6 (95.1–99.8) 99.8 (99.1–100)
a Test positive defined as positive for both the Capillus and Determine assays; test negative defined as negative for at least one of the assays.
b Test positive defined as positive for the assay; test negative defined as negative or indeterminate for the assay.
c Test positive defined as positive for both the Murex and Uniform assays; test negative defined as negative or indeterminate for at least one of the assays.
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